Optitropin Oxandrolone 50 mg tablets were submitted for independent testing to verify their composition and potency. The sample was provided by B Ware, an individual consumer with no known affiliations to a reseller, distributor, or manufacturer. The analysis was conducted by Janoshik Analytical, an independent laboratory specializing in pharmaceutical quality control.
The laboratory results determined measured concentrations of 51.25 mg, 48.84 mg, and 47.19 mg per tablet, resulting in an average potency of 49.09 mg, which equates to 98.18% of the labeled claim, with a variance ranging from +2.5% to -5.62%. This variability is within standard pharmaceutical tolerances.
Additionally, the Relative Standard Deviation (RSD%) was calculated at 4.16%, confirming that the tablets maintain consistent dosage uniformity. Since the RSD% is below the 6% threshold, the batch meets pharmaceutical compliance standards for uniformity.
This report is published to provide transparency and promote harm reduction by offering insight into product consistency and quality.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Oxandrolone
- Active Ingredient: Oxandrolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #48459
- Testing Ordered: 30 August 2024
- Sample Received: 4 September 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Component | Specification (Label Claim) | Measured Concentrations | Accuracy (Average) | Variance | RSD% | Compliance (RSD%) |
|---|---|---|---|---|---|---|
| Oxandrolone | 50 mg per tablet | 51.25 mg, 48.84 mg, 47.19 mg | 98.18% | +2.5% to -5.62% | 4.16% | ✅ Compliant (≤6%) |
Verification Details
- Verification URL: https://janoshik.com/tests/48459_1BHQELMI4VJW
Evaluation of Independent Testing
The analysis confirms that the Optitropin Oxandrolone 50 mg tablets are accurately dosed, with a slight variation well within standard tolerances. The measured concentrations indicate that the product remains consistently close to its labeled claim, ensuring quality and reliability.
Furthermore, the Relative Standard Deviation (RSD%) of 4.16% confirms that the tablets demonstrate content uniformity, reinforcing the manufacturer’s control over dosage consistency. Since RSD% is within the ≤6% pharmaceutical threshold, these results indicate that variability in potency is minimal and meets industry standards.
It is essential to recognize that this test was conducted on a single batch, and while the findings suggest strong quality control, they may not be representative of all batches. Further third-party testing across different batches is recommended to ensure ongoing quality assurance.
Additionally, this sample was submitted by an independent consumer with no commercial affiliations, reducing the risk of selection bias typically found in manufacturer- or reseller-funded testing.
Conclusion
The results confirm that Optitropin Oxandrolone 50 mg tablets are accurately dosed, with measured concentrations ranging from 51.25 mg to 47.19 mg, averaging 98.18% of the labeled claim. The Relative Standard Deviation (RSD%) of 4.16% indicates consistent dosage across tested tablets, meeting pharmaceutical uniformity standards.
This minor variation is within standard pharmaceutical tolerances, suggesting strong quality control for this batch.
Consumers are encouraged to continue verifying product quality through independent third-party testing, as this remains a crucial step in harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes only. The findings apply only to the batch tested and should not be generalized across all batches of the product. Readers are advised to critically assess all available data and consult with medical professionals before using such substances.
